跳转至内容
Merck
CN

SML0536

Sigma-Aldrich

依法韦伦

≥98% (HPLC), nonnucleoside reverse transcriptase inhibitor (NNRTI), powder

别名:

依法韦伦, (4S)-6-氯-4-(2-环丙基乙炔基)-1,4-二氢-4-(三氟甲基)-2H-3,1-苯并恶嗪-2-酮

登录查看公司和协议定价

关于此项目

经验公式(希尔记法):
C14H9ClF3NO2
CAS Number:
分子量:
315.67
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Product Name

依法韦伦, ≥98% (HPLC)

质量水平

方案

≥98% (HPLC)

表单

powder

旋光性

[α]/D -90 to -100°, c = 1 in methanol

颜色

white to beige

溶解性

DMSO: 15 mg/mL, clear

储存温度

−20°C

SMILES字符串

ClC1=CC=C2C([C@@](C#CC3CC3)(C(F)(F)F)OC(N2)=O)=C1

InChI

1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1

InChI key

XPOQHMRABVBWPR-ZDUSSCGKSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

具有Sustiva商品名的依法韦仑是一种含有苯和恶嗪-2-酮发色团的多环芳烃。

应用

依法韦仑已用于:
  • 评估其抗猪内源性逆转录病毒(PERV)活性
  • 细胞毒性检测
  • 通过结合时间密度泛函理论(TD-DFT)和光谱计算的方法,研究依法韦仑的溶质-溶剂效应

生化/生理作用

依法韦仑是一种非核苷类逆转录酶抑制剂(NNRTI)。它是一种抗HIV药物,常用于AIDs治疗的联合疗法。它是用于治疗人类免疫缺陷病毒(HIV)1型的高效抗逆转录病毒疗法(HAART)的一部分。
依法韦仑是一种非核苷类逆转录酶抑制剂(NNRTI);抗逆转录病毒。

特点和优势

这种化合物是 ADME 毒性研究的特色产品。点击此处发现更多特色 ADME 毒性产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

法律信息

Sustiva is a trademark of E. I. du Pont de Nemours and Company

警示用语:

Danger

危险声明

危险分类

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Kyle W Anderson et al.
The Journal of biological chemistry, 291(22), 11876-11886 (2016-04-09)
Cytochrome P450 46A1 (CYP46A1) is a microsomal enzyme and cholesterol 24-hydroxylase that controls cholesterol elimination from the brain. This P450 is also a potential target for Alzheimer disease because it can be activated pharmacologically by some marketed drugs, as exemplified
Jürgen K Rockstroh et al.
Journal of acquired immune deficiency syndromes (1999), 63(1), 77-85 (2013-02-16)
STARTMRK, a phase III noninferiority trial of raltegravir-based versus efavirenz-based therapy in treatment-naive patients, remained blinded until its conclusion at 5 years. We now report the final study results. Previously untreated patients without baseline resistance to efavirenz, tenofovir, or emtricitabine
Pietro Vernazza et al.
Journal of acquired immune deficiency syndromes (1999), 62(2), 171-179 (2013-01-19)
A 96-week clinical study was planned to estimate the antiviral activity and safety of lersivirine in treatment-naive HIV-1-infected patients. This ongoing international, multicenter, double-blind, randomized, Phase IIb exploratory study evaluates the efficacy and safety of 2 doses of lersivirine or
Michael M Lübtow et al.
Biomacromolecules, 20(8), 3041-3056 (2019-07-19)
Despite decades of research, our understanding of the molecular interactions between drugs and polymers in drug-loaded polymer micelles does not extend much beyond concepts such as "like-dissolves-like" or hydrophilic/hydrophobic. However, polymer-drug compatibility strongly affects formulation properties and therefore the translation
L B Avery et al.
Antimicrobial agents and chemotherapy, 57(3), 1409-1414 (2013-01-09)
Efavirenz (EFV) is one of the most commonly prescribed antiretroviral drugs (ARVs) for the treatment of HIV. Highly protein-bound drugs, like EFV, have limited central nervous system (CNS) penetration when measured using total drug concentration gradients between blood plasma (BP)

商品

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Discover Bioactive Small Molecules for ADME/Tox

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持